| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
DMPC does not have a pharmacological target; it is a formulation excipient and membrane model component. As a zwitterionic phospholipid, DMPC has a neutral charge at physiological pH, mimicking the neutral charge of the eukaryotic plasma membrane surface. It can form liposomes and lipid bilayers with a hydrophobic core to encapsulate lipophilic drugs while maintaining a hydrophilic outer surface to allow solubility in aqueous environments. DMPC is not an active pharmaceutical ingredient.
|
|---|---|
| ln Vitro |
In vitro, DMPC is used as a membrane model for studying protein-lipid interactions, membrane structure, and dynamics. It forms stable lipid bilayers and liposomes that can be used for drug encapsulation, membrane protein reconstitution, and biophysical characterization. DMPC is often used as a component in liposomal drug delivery systems to enhance the solubility, stability, and bioavailability of poorly water-soluble drugs. It is also used in commercial drug preparations to solubilize drugs for injection.
|
| ln Vivo |
In vivo, DMPC is used as an excipient in liposomal drug formulations. As a phospholipid, it can be administered as part of liposome-based drug delivery systems to improve the pharmacokinetics and biodistribution of encapsulated drugs. Liposomes containing DMPC can prolong circulation time and reduce drug toxicity. DMPC is not active itself and has no therapeutic indication. It is widely used in the development of liposomal formulations for cancer chemotherapy, antifungal therapy, and other applications.
|
| Enzyme Assay |
For liposome preparation, DMPC is dissolved in chloroform or another organic solvent at a concentration of 5-20 mg/mL. The lipid solution is dried under a stream of nitrogen or argon to form a thin film on the walls of a round-bottom flask. Residual solvent is removed under vacuum (e.g., rotavapor) for at least 30 minutes. The lipid film is hydrated with an aqueous buffer (e.g., PBS, pH 7.4) at a temperature above the phase transition temperature of DMPC (e.g., 37-50degC) to form multilamellar vesicles (MLVs). The suspension is sonicated or extruded through polycarbonate membranes (e.g., 100 nm pore size) to produce unilamellar liposomes of uniform size. Particle size is measured by dynamic light scattering (DLS). For drug encapsulation, a drug solution is added during the hydration step. Unencapsulated drug is removed by dialysis or ultracentrifugation. Encapsulation efficiency is determined by HPLC or spectrophotometry.
|
| Cell Assay |
For cell-based assays, liposomes containing DMPC are added to cells at various concentrations (e.g., 10-200 ug lipid/mL). Cellular uptake of encapsulated fluorescent markers (e.g., FITC-dextran) can be assessed by flow cytometry or confocal microscopy. Cytotoxicity is measured by MTT or LDH assay.
|
| Animal Protocol |
For in vivo studies, DMPC liposomes are prepared in sterile PBS or sucrose buffer. Typically, a lipid concentration of 10-50 mg/kg is administered intravenously (tail vein) to rodents. The pharmacokinetics and biodistribution of encapsulated drugs can be evaluated by measuring drug concentrations in blood and tissues (liver, spleen, lungs, kidneys) by HPLC or LC-MS/MS. Liposomal formulations can prolong the circulation half-life of encapsulated drugs compared to free drug. Efficacy studies are performed in disease models using drug-loaded liposomes. DMPC itself is not the active therapeutic.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for DMPC itself are not relevant as it is an excipient. When formulated into liposomes, the overall pharmacokinetic properties of the liposomal system are governed by the properties of the liposome (size, surface charge, PEGylation). DMPC liposomes are generally cleared by the reticuloendothelial system (RES), primarily in the liver and spleen. The half-life of conventional DMPC liposomes is relatively short (minutes to hours), but it can be prolonged by incorporating PEGylated lipids. DMPC has a molecular weight of 677.93, a molecular formula of C36H72NO8P, and an XLogP of 8.75, indicating high lipophilicity. It should be stored at -20degC as a powder, protected from moisture and oxidation.
|
| Toxicity/Toxicokinetics |
DMPC is considered non-toxic and is generally recognized as safe for use in pharmaceutical formulations. In cell-based assays, DMPC liposomes show minimal cytotoxicity at concentrations up to 200 ug/mL. In vivo, DMPC liposomes are well tolerated at doses up to 100 mg/kg. There are no reports of significant organ toxicity. DMPC is not an active drug and has no indication. It is listed as an inactive ingredient in FDA-approved drug products.
|
| References | |
| Additional Infomation |
Dimyristicophosphatidylcholine is a phosphatidylcholine in which the phosphatidyl group is designated as tetradecanoyl (myristicoyl). It is a synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes. It is used in commercial pharmaceutical formulations to solubilize injectable drugs. A synthetic phospholipid for liposomes and lipid bilayers for the study of biological membranes.
Drug Indications DL-Dimyristicophosphatidylcholine is not an active pharmaceutical ingredient and has no indications. Mechanism of Action As a phospholipid, DL-Dimyristicophosphatidylcholine can form micelles with a hydrophobic core to encapsulate lipophilic drugs while maintaining a hydrophilic outer layer, thereby improving the solubility of the drug in the aqueous environment of the blood or gastrointestinal tract. Pharmacodynamics DL-Dimyristicophosphatidylcholine is a water-soluble phospholipid used to solubilize injectable drugs. DMPC is a research-grade synthetic phospholipid and is not an active drug. It is widely used in liposome research, drug delivery systems, and membrane biophysics studies. Its phase transition temperature is approximately 23degC. It is a component of some commercial liposomal drug formulations (e.g., liposomal amphotericin B) and is used to solubilize poorly water-soluble drugs for injection. The CAS number is 18656-38-7. Store at -20degC as a powder, protected from moisture. The compound should be handled under inert atmosphere (N2 or Ar) to prevent oxidation. |
| Molecular Formula |
C36H72NO8P
|
|---|---|
| Molecular Weight |
677.93
|
| Exact Mass |
677.499
|
| CAS # |
18656-38-7
|
| PubChem CID |
26197
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.75
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
36
|
| Heavy Atom Count |
46
|
| Complexity |
765
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC
|
| InChi Key |
CITHEXJVPOWHKC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-21-19-17-15-13-11-9-7-2/h34H,6-33H2,1-5H3
|
| Chemical Name |
2,3-di(tetradecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4751 mL | 7.3754 mL | 14.7508 mL | |
| 5 mM | 0.2950 mL | 1.4751 mL | 2.9502 mL | |
| 10 mM | 0.1475 mL | 0.7375 mL | 1.4751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
